Table 2.
Characteristics of the clinical metabotypes
| Favorable clinical metabotype (n = 99)* | Unfavorable clinical metabotype (n = 104)** | |
|---|---|---|
| n (%) | ||
| Men | 31 (31.3) | 39 (37.5) |
| Statin users | 5 (5.1) | 24 (23.1) |
| Anti-inflammatory drug users | 3 (3) | 4 (3.8) |
| Premenopausal women | 48 (71) | 18 (28) |
| Women using hormonal contraceptives | 27 (40) | 5 (8) |
| Mean (SD) | ||
| Age (years) | 44 (12) | 55 (10) |
| BMI (kg/m2) | 30.9 (5.1) | 33.3 (4.7) |
| Waist circumference (cm) | 101.2 (14.0) | 111.9 (12.0) |
| HbA1c (mmol/mol) | 27 (14) | 33 (16) |
| Total-C (mmol/L) | 5.0 (0.9) | 5.1 (1.0) |
| LDL-C (mmol/L) | 3.3 (0.8) | 3.5 (1.0) |
| Median (IQR) | ||
| HDL-C (mmol/L) | 1.4 (0.5) | 1.3 (0.4) |
| Triglycerides (mmol/L) | 1.15 (0.56) | 1.46 (1.02) |
| Lp(a) (mg/L) | 316 (498) | 202 (425) |
| Fasting glucose (mmol/L) | 4.9 (0.4) | 5.8 (0.8) |
| Insulin (pmol/L) | 61 (42) | 100 (77) |
| 2-h glucose (mmol/L) | 4.7 (1.4) | 6.6 (2.6) |
| Systolic BP (mmHg) | 116 (14) | 124 (21) |
| Diastolic BP (mmHg) | 68 (12) | 72 (13) |
| CRP (mg/L) | 2.1 (3.1) | 3.8 (5.1) |
BMI, body mass index; HbA1c, glycated haemoglobin; C, cholesterol; LDL, low-density lipoprotein; HDL, hgh-density lipoprotein; Lp(a), lipoprotein a; BP, blood pressure; CRP, C-reactive protein
*Age, n = 96; BMI and waist circumference, n = 98; Lp(a), n = 50; 2-h glucose, n = 97
**Age and BMI, n = 103; fat mass, n = 98; LDL-C and HDL-C, n = 102; Lp(a), n = 66